Shots:
- Wanchunbulin to receive $30M up front, $170M as regulatory and sales milestone & is eligible to receive $15M as equity investment at a pre-money valuation of $560M
- Hengrui gets exclusive rights to commercialize & co-develop plinabulin in Greater China and will be accountable for all costs associated with the commercialization of plinabulin in the territory while Wanchunbulin will hold the manufacturing rights of plinabulin in the territory
- Hengrui will fund 50% of the clinical development costs for additional indications of plinabulin in the territory & Wanchunbulin will be responsible for 100% of clinical and regulatory costs for the first two indications to prevent CIN & NSCLC
Click here to read full press release/ article | Ref: Beyond Spring | Image: Yahoo Finance
The post BeyondSpring Signs an Exclusive Agreement with Jiangsu Hengrui to Co- Develop & Commercialize Plinabulin in Greater China first appeared on PharmaShots.
